Trial results for the study "Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer" (NCT02530489) investigating atezolizumab in combination with nab-paclitaxel were posted on ClinicalTrials.gov on 2026-02-17. This Phase 2 trial enrolled 37 participants with triple negative breast cancer.
Background
Atezolizumab was investigated in this study for its potential role in treating triple negative breast cancer (TNBC). TNBC is a form of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) protein overexpression. This makes TNBC a challenging subtype to treat, as it does not respond to hormone therapy or HER2-targeted therapies.
Trial design
The study NCT02530489 was a Phase 2 trial with an enrollment of 37 participants. The trial investigated the use of atezolizumab and nab-paclitaxel before surgery in patients diagnosed with triple negative breast cancer, specifically breast adenocarcinoma and invasive breast carcinoma.
Key results
The trial reported outcomes related to "RCB Status" for the atezolizumab and nab-paclitaxel group. The measurements included counts of participants, with reported values of 12 participants, 5 participants, and 20 participants for this outcome.
What this means
The posted results provide data on "RCB Status" in participants with triple negative breast cancer treated with atezolizumab and nab-paclitaxel. As a Phase 2 study, these findings contribute to the understanding of this combination therapy in the neoadjuvant setting for this challenging cancer subtype. Further interpretation would require additional context regarding the specific categories within "RCB Status" and comparative data.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT02530489, titled "Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer," were posted on 2026-02-17 on clinicaltrials.gov.